# US 2023/0142627 A1 · Pharmaceutical compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0142627 A1
- Document ID: US20230142627A1
- Status: Published application
- Kind: A1
- Application number: 17/977,371
- Filed: 2022-10-31
- Published: 2023-05-11
- Earliest claimed: 2015-08-03
- Assignees: Pop Test Oncology LLC
- Applicants: Pop Test Oncology LLC
- Inventors: Randice Lisa Altshul; Neil David Thiese; Andreas J. Kesel; Myron Rapkin; Rebecca O'Brien; Anthony Arment
- Web page: https://patentgrep.com/patent/US20230142627A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- C07H 19/06: Pyrimidine radicals
- C07H 19/067: with ribosyl as the saccharide radical
- C07J 17/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton (cardanolide, bufanolide C07J19/00)
- C07J 41/0005: {the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

## Claims

### Claim 1

A pharmaceutical composition comprising:
at least one active agent selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
optionally, at least one auxiliary agent selected from the group consisting of opiates.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is in a dosage form selected from the group consisting of a capsule, a tablet, a smart pill delivery device, and a smart capsule delivery device.

### Claim 3

A method of treatment, comprising:
selecting a patient in need of treating or preventing a condition selected from the group consisting of nicotine, opioids, methamphetamine, and/or alcohol addiction; nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety; and nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms; and
administering to the patient in need of treating or preventing the condition an effective amount of at least one active agent selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;

### Claim 4

A method of treatment, comprising:
selecting a patient in need of treating or preventing a condition selected from the group consisting of nicotine, opioids, methamphetamine, and/or alcohol addiction; nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety; and nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms;
administering a composition comprising:
i) a therapeutic selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
ii) at least one additional therapeutic agent(s) selected from the group consisting of anxiolytics, antidepressants, neuroleptics, or other psychotropic medications and combinations thereof; and
iii) at least one pharmaceutically acceptable carrier, wherein the therapeutic and the at least one additional therapeutic agents are each present in an amount which, in combination, is a therapeutically effective amount for treating or preventing the condition.

### Claim 5 (depends on 4)

The method of claim 4 wherein the additional therapeutic agent is selected from the group consisting of at least one anti-anxiety drug, at least one anti-depressant drug, and at least one neuroleptic medication and combinations thereof, wherein the at least one anti-anxiety drug is selected from the group consisting of alprazolam, bromazepam, diazepam, lorazepam, clonazepam, temazepam, oxazepam, fluni-trazepam, triazolam, chlordiazepoxide, flurazepam, esta-zolam, nitrazepam, and pharmaceutically acceptable salts, isomers, and mixtures thereof; and/or at least one anti-depressant drug selected from the group consisting of citalopram, escitalopram oxalate, fluoxetine, fluvoxamine, paroxetine, sertraline, dapoxetine; venlafaxine and duloxetine; harma-line, iproniazid, isocarboxazid, nialamide, paigyline, phenelzine, selegiline, toloxatone, tranylcypromine, brofar-omine, moclobemide; amitriptyline, amoxapine, butrip-tyline, clomipramine, desipramine, dibenzepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, trimipramine; maprotiline, mianserin, nefazodone, trazodone, and pharmaceutically acceptable salts, isomers, and combinations thereof, and/or at least one neuroleptic drug selected from the group consisting of Haloperidol, Droperidol, Benperidol, Triperi-dol, Melperone, Lenperone, azaperone, Domperidone, risperidone, Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Mesoridazine, Periciazine, Promazine, Triflupromazine, Levomepromazine, Promethazine, Pimozide, Cyamemazine, Chlorprothixene, Clopenthixol, Flupenthixol, Thiothixene, Zuclopenthixol, Clozapine, Olanzapine, Risperidone, Que-tiapine, Ziprasidone, Amisulpride, Asenapine, Paliperidone, Iloperidone, Zotepine, Sertindole, Lurasidone, Aripiprazole, and pharmaceutically acceptable salts, isomers, and combinations thereof.

### Claim 6

A method of treating or preventing nicotine, opioids, methamphetamine, and/or alcohol addiction, nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety, and/or nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms in a patient, comprising the steps of:
a) obtaining a test sample from the patient using a test sample collection unit;
b) combining said test sample with a buffering system to form a mixture in a reaction unit;
c) measuring a parameter of the mixture to determine a blank measurement;
d) combining said test sample and buffer mixture with a labeled ligand which binds cortisol in the reaction unit to produce an assay solution; or combining said test sample and buffer mixture and delivering it to a carrier containing a labeled ligand which binds cortisol in the reaction unit to produce an assay immobilized complex;
e) measuring a parameter of said assay solution or complex;
f) comparing the measurement of the assay solution relative to the blank measurement;
g) determining the patient's circulating cortisol levels based on the change of the measurement;
h) comparing the measured cortisol levels to a predetermined reference range cortisol levels, wherein when the level of cortisol is elevated relative to the predetermined reference range, then the patient has elevated cortisol, and thus is suitable for GCR (glucocorticoid receptor) antagonist therapy; and
i) when the patient is suitable the therapeutic is selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
thereby treating or preventing nicotine, opioids, methamphetamine, and/or alcohol addiction, nicotine, opioids, methamphetamine,
and/or alcohol addiction induced anxiety, and/or nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms in the patient.

### Claim 7 (depends on 6)

The method of claim 6, wherein the patient's test sample is selected from the group consisting of saliva, blood, plasma, serum, urine, other bodily fluids, and combinations thereof.

### Claim 8 (depends on 6)

The method of claim 6, wherein the sample is obtained from the patient one time, selected from the group consisting of morning, noon, and evening.

### Claim 9 (depends on 6)

The method of claim 6, wherein the sample is obtained from the patient over more than one time, and the predetermined time is selected to determine the nature of the cortisol circadian rhythm (including its possible disruption or elimination) from the group consisting of morning, noon, and evening.

### Claim 10 (depends on 6)

The method of claim 6, wherein the sample is obtained from the patient over consecutive days.

### Claim 11 (depends on 6)

The method of claim 6, wherein the method is to determine the circadian cycle of the cortisol levels in the patient, and the predetermined time is selected from the group consisting of hourly, every 4 hours, every 6 hours, every 8 hours, and every 12 hours.

### Claim 12 (depends on 6)

The method of claim 6, wherein the predetermined reference range is a medically standard reference range.

### Claim 13 (depends on 6)

The method of claim 6, wherein the predetermined reference range is the patient's previously measured level.

### Claim 14 (depends on 6)

The method of claim 6, wherein the ligand is detectably labeled with a moiety selected from the group consisting of a radioisotope, a fluorophore, a quencher of fluorescence, an enzyme, an affinity tag, and an epitope tag.

### Claim 15 (depends on 6)

The method of claim 6, wherein said measuring of said parameter of said mixture and said assay solution is performed using a method selected from spectroscopic, photochemical, radiochemical, biochemical, enzymatic, immunochemical, chemical label displacement, surface plasmon resonance, fluorescence resonance energy transfer, fluorescence quenching, lateral flow, and fluorescence polarization means.
